Journal article
Switching the Histamine H2 Receptor Antagonist Famotidine to Nonprescription Status in Canada
Abstract
The aim of this study was to compare the direct medical costs associated with the treatment of patients with heartburn/nonulcer dyspepsia under 2 scenarios: (i) no nonprescription histamine H2 receptor antagonist (H2RA) is available (the ‘status quo scenario’); and (ii) the H2RA famotidine (at a daily dosage of 10mg) is available over-the-counter (OTC) at retail pharmacies (the ‘OTC scenario’).We employed a decision analysis model over a …
Authors
Tasch RF; Goeree R; Henke CJ; O’Brien BJ
Journal
PharmacoEconomics, Vol. 9, No. 1, pp. 61–75
Publisher
Springer Nature
Publication Date
January 1996
DOI
10.2165/00019053-199609010-00007
ISSN
1170-7690